An observational study in Coronary Artery Bypass Grafting, Off-pump Coronary Artery Bypass and Minimally Invasive Cardiac Surgery, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Peking University Third Hospital · Observational
The goal of this single-center prospective cohort study is to compare perioperative safety metrics and follow-up survival analyses in patients receiving Minimally Invasive Cardiac Surgery Coronary Artery Bypass Grafting(MICS-CABG) and Off-Pump Coronary Artery Bypass(OPCAB). The main question it aims to answer is:
Is the bridge vessel patency rate of patients in the MICS-Notouch group noninferior to that of a saphenous vein bridge with conventional open-chest bypass?
Participants will be divided into two groups:
Exposure group (MICS-Notouch group): non-extracorporeal circulation multiple coronary artery bypass grafting surgery performed under direct visualization of a small incision in the left chest, including the application of LIMA (left internal mammary artery) + SVG (saphenous vein) multiple bypass grafting.
Control group (OPCAB group): conventional median chest opening, non-extracorporeal circulation multi-branch coronary artery bypass graft surgery.
STATUS OF THE STUDY: Coronary Artery Bypass Grafting (CABG) surgery and Percutaneous Coronary Intervention (PCI) are important methods to address myocardial ischemia in coronary artery disease. CABG surgery, with its internal mammary artery bridging, can achieve a patency rate of more than 90% at 5 years after the procedure, which is currently the gold standard for the treatment of coronary artery disease. Although with the development of drug-eluting stents, coronary spinning mill technology and FFR technology, the incidence of mid- and long-term major adverse cardiovascular and cerebrovascular events (MACCE) of PCI treatment has been greatly reduced, CABG surgery is still the first choice for patients with complex coronary artery disease, left main stem disease and diabetes mellitus and other high-risk patients. However, traditional CABG surgery requires splitting the sternum, which is highly traumatic compared with PCI treatment, and carries a high surgical risk for patients with advanced age and comorbidities, as well as the risk of non-healing of the sternum. Minimal Invasive Cardiac Surgery-Coronary Artery Bypass Grafting surgery (MICS-CABG surgery) can reduce surgical trauma, surgical blood transfusion, and shorten postoperative hospitalization due to the avoidance of sternum injury.
Due to space constraints, MICS-CABG surgery cannot apply a proximal anastomosis to the ascending aorta and requires the use of a special sidewall clamp to clamp the ascending aorta, which poses two potential risks: 1. In patients with calcification and thickening of the ascending aorta, clamping of the ascending aorta may cause rupture of the intimal plaque and dislodgement, which can lead to the risk of cerebral infarction and peripheral arterial embolism; 2. minimal incision In bypass surgery, the proximal anastomosis of the ascending aorta has a very low tolerance rate. Due to the deep location of the ascending aorta, the surgical field and operating space are limited, and the suture is extremely difficult, if the anastomosis process occurs in the case of vascular tear, anastomotic leakage, or dislodgement of the sidewall clamp, it will cause serious uncontrollable aortic bleeding, which may endanger the patient's life in a short period of time.
SIGNIFICANCE: The optimization of the MICS-CABG surgical protocol through this topic reduces the surgical risk and removes the obstacles for the promotion of this technology.
In order to solve the problem of proximal anastomosis of MICS-CABG surgery in patients with calcification of the ascending aorta and to reduce the difficulty and risk of surgery. In 2020, our center began to explore the minimally invasive bypass surgery of ascending aorta non-touch (No-touch) technology, which refers to the bypass surgery without any manipulation of the ascending aorta, the proximal anastomosis of the bridge vessel in the axillary artery, through the first intercostal space of the bridge vessel to the thoracic cavity for the distal continuation of the anastomosis. The advantages of this technique are: 1) avoiding ascending aortic manipulation eliminates the risk of cerebral infarction and peripheral arterial embolism caused by plaque dislodgement from the ascending aorta; 2) the axillary artery rarely exists in calcification, and the vascular condition is good; 3) the axillary artery is simple to reveal, with plenty of room for maneuvering, and it can be anastomosed under direct vision, which greatly reduces the difficulty of the procedure, and if the anastomosis bleeds after the completion of the anastomosis, the bleeding is simple to stop, which decreases the risk of surgical manipulation.
This study will evaluate the safety and efficacy of this technique in a prospective cohort study. If the safety and efficacy of this technique are confirmed to be good, it will greatly expand the indications of this cutting-edge technique of MICS-CABG, optimize the surgical plan, reduce the surgical difficulty and shorten the learning curve.
Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients to undergo coronary artery bypass grafting due to coronary heart disease.
Exclusion Criteria:
Patients enrolled underwent non-extracorporeal coronary artery bypass grafting under direct vision through a small left thoracotomy, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein graft) multibranch bypass grafts.
Procedure: Non-extracorporeal multiple coronary artery bypass graft (CABG) performed under direct visualization through a small incision in the left side of the chest.
Patients enrolled underwent conventional median open-heart surgery with multiple coronary artery bypass grafting under off-pump circulation.
Procedure: Multi-branch coronary artery bypass grafting with conventional median open heart and off-pump circulation
Exposure group (MICS-Notouch group): Direct visualization non-extracorporeal coronary artery bypass grafting with a small left chest incision, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein) multibranch bypass grafting.
Control Group (OPCAB Group): Conventional median open multiple coronary artery bypass grafting with extracorporeal circulation.
Early Postoperative Saphenous Vein Bridge Vessel Patency Rate
The patients' bridge vessel patency is assessed by angiography within 1-14 days after surgery.
Time frame: 1-14 days after surgery
Early Postoperative Saphenous Vein Bridge Vessel Patency Rate
The patients' bridge vessel patency is assessed by Coronary Computed Tomography Angiography within 1-14 days after surgery.
Time frame: 1-14 days after surgery
Perioperative Safety Indicators
The following variables were considered: transfusion volume, extracorporeal circulation transfer rate, IABP and ECMO utilization rate, reoperation rate, incidence of poor wound healing, 1-year postoperative bridging vessel patency rate (CT or angiography), incidence of perioperative MACCE, incidence of atrial fibrillation, incidence of renal failure, incidence of re-tracheal intubation, duration of postoperative hospitalization, duration of ICU stay, duration of mechanical ventilation, and hospitalization costs.
Time frame: One year after surgery
Survival Analysis
The occurrence of MACCE (including all-cause mortality, re-bypass or stenting, acute infarction, and stroke), as well as readmission for infarction or heart failure at 1, 3, 6, and 12 months postoperatively, will be monitored.
Time frame: One year after surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital